← Cellectis S.A. (CLLS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Cellectis S.A. (CLLS)
Biological Products, (No Diagnostic Substances) · market cap $105M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-06 (est.)
Earnings
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Cellectis S.A. (CLLS) is a French biotherapeutics company with 216 employees and a ~$284M market cap trading near $3.09, focused on allogeneic CAR-T cell therapy. Its lead asset UCART22 is in Phase 2 for B-cell Acute Lymphoblastic Leukemia, with a second Phase 2 asset UCART20x22 targeting B-cell Non-Hodgkin Lymphoma. The nearest disclosed catalyst is an August 3, 2026 earnings report rated modest importance.
The catalyst path
- 2026-11-06 (est.)Earningsimp 5/10
- 2027-08-15 (est.)Phase 2 · UCART20x22imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| UCART22 | Phase 2 | B-cell Acute Lymphoblastic Leukemia |
| UCART20x22 | Phase 2 | B-cell Non-Hodgkin Lymphoma (B-NHL) |
Price & technical context
3-month
-57.6%
6-month
-58.6%
12-month
-50.9%
52-wk range
$1.38–$5.35
vs 50-day MA
-46.8%
vs 200-day MA
-59.1%
Realized vol
90.6%
Max drawdown
-74.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CLLS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.